In Vivo Adipose
Tissue Engineering
Transforming fat from a disease driver into a therapeutic target.
Lipovectra develops medicines that reprogram white adipose tissue in vivo in order to address major unmet medical needs and medical aesthetics.
Our Mission
Develop Medicines that Reprogram Fat Directly Inside Patients
White adipose tissue (WAT) is a key driver for countless diseases from sleep apnea to heart failure. Despite this, no approved medicines aim to directly modulate WAT biology. This is the unmet need we are solving.
Our ex vivo human fat lets us design drugs that safely and precisely reprogram human WAT. The result: in vivo adipose tissue engineering.